259 related articles for article (PubMed ID: 15722066)
1. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial.
Oddsson K; Leifels-Fischer B; de Melo NR; Wiel-Masson D; Benedetto C; Verhoeven CH; Dieben TO
Contraception; 2005 Mar; 71(3):176-82. PubMed ID: 15722066
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
3. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.
Oddsson K; Leifels-Fischer B; Wiel-Masson D; de Melo NR; Benedetto C; Verhoeven CH; Dieben TO
Hum Reprod; 2005 Feb; 20(2):557-62. PubMed ID: 15539438
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.
van den Heuvel MW; van Bragt AJ; Alnabawy AK; Kaptein MC
Contraception; 2005 Sep; 72(3):168-74. PubMed ID: 16102549
[TBL] [Abstract][Full Text] [Related]
5. The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study.
Magnusdóttir EM; Bjarnadóttir RI; Onundarson PT; Gudmundsdóttir BR; Geirsson RT; Magnusdóttir SD; Dieben TO
Contraception; 2004 Jun; 69(6):461-7. PubMed ID: 15157790
[TBL] [Abstract][Full Text] [Related]
6. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
[TBL] [Abstract][Full Text] [Related]
7. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
[TBL] [Abstract][Full Text] [Related]
9. Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing.
Roumen F
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():19-24; discussion 37-9. PubMed ID: 12659398
[TBL] [Abstract][Full Text] [Related]
10. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing.
Bruni V; Pontello V; Luisi S; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):65-71. PubMed ID: 18358586
[TBL] [Abstract][Full Text] [Related]
11. Lower hormone dosage with improved cycle control.
Vree M
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
[TBL] [Abstract][Full Text] [Related]
12. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
[TBL] [Abstract][Full Text] [Related]
13. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials.
Roumen FJ
Contraception; 2007 Jun; 75(6):420-9. PubMed ID: 17519147
[TBL] [Abstract][Full Text] [Related]
14. Complete and robust ovulation inhibition with NuvaRing.
Killick S
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():13-8; discussion 37-9. PubMed ID: 12659397
[TBL] [Abstract][Full Text] [Related]
15. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
Roumen FJ; Dieben TO
Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
[TBL] [Abstract][Full Text] [Related]
16. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
[TBL] [Abstract][Full Text] [Related]
17. Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone).
Mohamed AM; El-Sherbiny WS; Mostafa WA
Int J Gynaecol Obstet; 2011 Aug; 114(2):145-8. PubMed ID: 21669426
[TBL] [Abstract][Full Text] [Related]
18. The combined contraceptive vaginal device (NuvaRing): a comprehensive review.
Sarkar NN
Eur J Contracept Reprod Health Care; 2005 Jun; 10(2):73-8. PubMed ID: 16147810
[TBL] [Abstract][Full Text] [Related]
19. The combined contraceptive vaginal ring, NuvaRing, and tampon co-usage.
Verhoeven CH; Dieben TO
Contraception; 2004 Mar; 69(3):197-9. PubMed ID: 14969666
[TBL] [Abstract][Full Text] [Related]
20. Ethinylestradiol + etonogestrel contraceptive vaginal ring: new drug. Possibly useful in some situations.
Prescrire Int; 2006 Apr; 15(82):50-3. PubMed ID: 16604729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
